Tau-MEDICAL Co., Ltd.
Tau-Medical is dedicated to developing innovative, minimally invasive cardiovascular technologies targeting specific areas within the heart, such as valves and ventricular septum. The company focuses on treatments for heart diseases including tricuspid regurgitation, mitral regurgitation, hypertrophic cardiomyopathy, and heart arrhythmia, with a mission to set new standards in cardiovascular health through advanced medical devices and therapies.
Industries
Nr. of Employees
small (1-50)
Tau-MEDICAL Co., Ltd.
#407, ABC Center, Pusan National University Yangsan Campus, Yangsan, Korea
Patents
Products
Temporary transcatheter tricuspid spacer implant (temporary bridge therapy)
A temporary catheter-delivered implant intended to reduce tricuspid regurgitation as a short-term or pre-operative bridge therapy prior to definitive surgical or device repair.
Transcatheter mitral loop cerclage annuloplasty system
A transcatheter cerclage annuloplasty system that applies a loop-based annuloplasty to reduce mitral regurgitation and promote left ventricular reshaping.
Transvenous intramyocardial RF ablation catheter system for septal reduction
A transcatheter RF ablation system delivering RF energy via electrode-tip catheters with internal cooling, intended to ablate targeted septal myocardium for septal reduction in hypertrophic obstructive cardiomyopathy and other indications.
Cerclage parahisian septal pacing lead and delivery system
A transvenous cerclage-based pacing lead and delivery technique designed to allow parahisian or His-bundle area pacing via a septal perforator venous route.
Temporary transcatheter tricuspid spacer implant (temporary bridge therapy)
A temporary catheter-delivered implant intended to reduce tricuspid regurgitation as a short-term or pre-operative bridge therapy prior to definitive surgical or device repair.
Transcatheter mitral loop cerclage annuloplasty system
A transcatheter cerclage annuloplasty system that applies a loop-based annuloplasty to reduce mitral regurgitation and promote left ventricular reshaping.
Transvenous intramyocardial RF ablation catheter system for septal reduction
A transcatheter RF ablation system delivering RF energy via electrode-tip catheters with internal cooling, intended to ablate targeted septal myocardium for septal reduction in hypertrophic obstructive cardiomyopathy and other indications.
Cerclage parahisian septal pacing lead and delivery system
A transvenous cerclage-based pacing lead and delivery technique designed to allow parahisian or His-bundle area pacing via a septal perforator venous route.
Services
Design and assembly of catheter-based prototypes and execution/support of preclinical in vivo studies (including porcine models) to evaluate safety and performance.
Coordination and management of early feasibility and exploratory clinical studies, including interactions with regulatory authorities and clinical sites.
Manufacturing of investigational medical devices in cGMP/GMP-certified facilities to supply preclinical and clinical studies.
Joint development agreements and technical collaborations for RF systems and other device technologies with specialized manufacturers and technology partners.
Preparation for national regulatory submissions and early-feasibility approvals, and planning toward CE/FDA pathways for device commercialization.
Design and assembly of catheter-based prototypes and execution/support of preclinical in vivo studies (including porcine models) to evaluate safety and performance.
Coordination and management of early feasibility and exploratory clinical studies, including interactions with regulatory authorities and clinical sites.
Manufacturing of investigational medical devices in cGMP/GMP-certified facilities to supply preclinical and clinical studies.
Joint development agreements and technical collaborations for RF systems and other device technologies with specialized manufacturers and technology partners.
Preparation for national regulatory submissions and early-feasibility approvals, and planning toward CE/FDA pathways for device commercialization.
Expertise Areas
- Transcatheter structural heart device development
- Electrophysiology device development and pacing techniques
- Radiofrequency ablation system development
- Preclinical and early-feasibility clinical studies
Key Technologies
- Catheter-based delivery systems
- Radiofrequency (RF) ablation technology
- Transcatheter annuloplasty / cerclage techniques
- Cerclage/parahisian septal pacing leads
News & Updates
Tau Medical is excited to be participating in the upcoming TCT 2021 Conference (Nov. 4-6) and will share their new state-of-the-art cardiovascular technology during the show.
Tau Medical announced the first human use of TIRA, an RF ablation technology treating Hypertrophic Obstructive Cardiomyopathy (HoCM). The procedure was performed at Pusan National University Yangsan Hospital.
Tau Medical has been researching and developing minimally invasive surgical methodologies for treating various heart diseases. They are actively preparing for global clinical trials with top-tier cardiac clinical experts in the USA and Europe.
Tau Cardio Inc. (US) was established in 2020. The company has secured Series B funding of USD 22 million and aims to expand its clinical trials and market presence.
Tau Medical and RF Medical have signed a joint development agreement to develop RF ablation systems for hypertrophic cardiomyopathy.
Research on the Pivot-TR system, a device for reducing tricuspid regurgitation, featuring 3D leaflet and atraumatic anchor.
Tau Medical is excited to be participating in the upcoming TCT 2021 Conference (Nov. 4-6) and will share their new state-of-the-art cardiovascular technology during the show.
Tau Medical announced the first human use of TIRA, an RF ablation technology treating Hypertrophic Obstructive Cardiomyopathy (HoCM). The procedure was performed at Pusan National University Yangsan Hospital.
Tau Medical has been researching and developing minimally invasive surgical methodologies for treating various heart diseases. They are actively preparing for global clinical trials with top-tier cardiac clinical experts in the USA and Europe.
Tau Cardio Inc. (US) was established in 2020. The company has secured Series B funding of USD 22 million and aims to expand its clinical trials and market presence.
Tau Medical and RF Medical have signed a joint development agreement to develop RF ablation systems for hypertrophic cardiomyopathy.
Research on the Pivot-TR system, a device for reducing tricuspid regurgitation, featuring 3D leaflet and atraumatic anchor.